Assembly Biosciences Receives $75 Million Gilead Fee
Assembly Biosciences received its first $75 million collaboration extension fee from Gilead and projects its cash runway into 2029. It also initiated a Phase 2 study of ABI-6250 and elected a 40% U.S. cost and profit share for its HSV inhibitor program.
Assembly Biosciences received its first $75M collaboration extension fee from Gilead and projects cash runway into 2029. It initiated a Phase 2 study of ABI-6250 in chronic hepatitis delta and elected a 40% U.S. cost and profit share for its HSV inhibitor program.Material DetailsContext by AI Analy…